Author: Ravi Shankar

FALLS CHURCH, Va., Oct. 20, 2026 (GLOBE NEWSWIRE) — Northrop Grumman Corporation (NYSE: NOC) has released its third quarter 2026 financial results. A copy of the earnings release has been furnished in the company’s Form 8-K filing and is also available on the company’s investor relations website at http://investor.northropgrumman.com.

Earnings Call Webcast

As previously announced, Northrop Grumman will webcast its earnings conference call at 9:30 a.m. Eastern time today. A live audio broadcast of the conference call will be available on http://investor.northropgrumman.com.

About Northrop Grumman

Northrop Grumman is a leading global aerospace and defense technology company. Our pioneering solutions equip our customers with the capabilities they need to connect and protect the world, and push the boundaries of human exploration across the universe. Driven by a shared purpose to solve our customers’ toughest problems, our employees define possible every day.

Media Contact

News Bureau
newsbureau@ngc.com

Randy Sinclair
randy.sinclair@ngc.com

Digitalist Group Plc    Inside information     20 October 2026 at 13:05

Digitalist Group structures its financing

Digitalist Group Plc’s (“Digitalist Group” or “Company”) has agreed with Turret Oy Ab (“Turret”) on a loan amounting to EUR 1,100,000 (the “Loan”) in order to strengthen the Company’s working capital. The Company has the right to withdraw the Loan in instalments by 31 December 2026 at the latest. The Loan was granted on market terms and it will fall due on 30 September 2027.

Turret is Digitalist Group’s largest shareholder.

According to company law legislation relating to related party transactions Digitalist Group’s board members Peter Eriksson and Andreas Rosenlew have not participated in the decision making regarding the Loan.

DIGITALIST GROUP PLC

Board of Directors

For further information, please contact:

Digitalist Group Plc

CEO Magnus Leijonborg,
Tel. +46 76 315 8422, magnus.leijonborg@digitalistgroup.com

Chairman of the Board Esa Matikainen,
Tel. +358 40 506 0080, esa.matikainen@digitalistgroup.com

Distribution:
Nasdaq Helsinki Ltd
Main media

https://digitalist.global

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Advanced Medical Solutions Group Plc
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Advisor & Joint Broker to Advanced Medical Solutions Group plc
(d)        Date dealing undertaken:	19th October 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchase	11,365	282.25	282.25
Ordinary shares	Sales	4,143	282.5	282.5

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	20th October 2026
Contact name:	Gary Darch
Telephone number:	0207 597 4549

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

VisionRF, GhostSight and DeepWave RF Form Part of Company’s Developing Multi-Domain Sensing Architecture

WEST HOLLYWOOD, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) — VisionWave Holdings, Inc. (Nasdaq: VWAV) (“VisionWave” or the “Company”) today highlighted its developing portfolio of radio-frequency (“RF”), radar and electronic-warfare technologies designed to extend sensing and electromagnetic awareness across autonomous ground and aerial systems.

VisionWave is developing multiple sensing technologies intended to address different portions of the electromagnetic spectrum and different mission environments, including VisionRF, GhostSight and DeepWave RF, together with electronic-warfare and spectrum-monitoring payload concepts. 

“Autonomous platforms are only as effective as their ability to understand the environment around them,” said Douglas Davis, Chief Executive Officer and Executive Chairman of VisionWave. “We view RF sensing, radar, optical intelligence and AI as complementary components of a broader sensing architecture rather than isolated technologies.”

VisionRF

VisionRF is under development for applications including threat detection, infrastructure inspection and non-line-of-sight detection. VisionRF has not completed independent third-party validation, and its detection performance has not been demonstrated in an operational environment. The Company is pursuing commercialization efforts with third parties. The parties have not entered into a definitive commercialization agreement, and there can be no assurance that these efforts will result in a product, a customer or revenue. 

GhostSight

GhostSight is a developing hybrid passive-radar architecture based on a passive receiver layer with cooperative illumination.

The architecture is being designed to provide detection capability without reliance on a dedicated emitting radar site of the Company’s own. Cooperative illumination depends on a radio-frequency illumination source; the architecture is therefore designed to avoid a dedicated emitter, not to operate without any illumination. 

Electronic Warfare and Spectrum Awareness

VisionWave is also developing electronic-warfare and spectrum-monitoring payload concepts intended for integration with the VARAN ground platform and TALON aerial systems.

The Company’s modular architecture is intended to allow sensing payloads to use common platform interfaces, potentially enabling autonomous assets to transition among ISR, electronic-warfare, sensing and logistics roles through mission-module changes. 

DeepWave RF

DeepWave RF is an early-stage technology combining RF, artificial intelligence and software-defined radio concepts for subsurface geological sensing across potential oil, gas and mineral applications. The technology remains under development and has not been commercially demonstrated. The Company has not conducted or commissioned independent third-party verification of DeepWave RF’s subsurface detection capability, no mineral resource, mineral reserve or oil and gas reserve estimate has been prepared using it, and it has not generated revenue. 

“Our longer-term objective is to connect sensing directly into the STRATUM intelligence environment,” Davis added. “That would allow information collected across RF, radar, optical and other sensor modalities to contribute to a common autonomous mission picture.”

The technologies described herein remain under development, are not commercially available and have not generated revenue. None has completed independent third-party validation, and there can be no assurance that any of them will be completed or will achieve their intended technical or commercial objectives. Their development, demonstration, export and sale are subject to export-authorization, spectrum and other regulatory requirements.

ABOUT VISIONWAVE

VisionWave Holdings, Inc. (Nasdaq: VWAV) is a defense and advanced sensing technology company developing AI-driven, RF-based sensing, autonomy, and computational acceleration technologies for defense, homeland security, and commercial infrastructure applications. VisionWave’s mission is to connect defense innovation with civilian progress through shared core technologies intended for use across air, land and fixed-site environments. The Company’s website is https://www.vwav.inc. Information contained on, or accessible through, the Company’s website is not incorporated by reference into, and does not form a part of, this press release or any filing of the Company with the Securities and Exchange Commission. Certain of the platforms, payloads, sensing technologies and software described in this press release are in development, have not completed testing or qualification, are not commercially available and have not generated material revenue.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are generally identified by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “project,” “forecast,” “predict,” “target,” “objective,” “strategy,” “designed to,” “intended to,” “concept,” “under development” and similar expressions, or by statements that events or trends “may,” “will,” or “could” occur. Forward-looking statements in this press release include, without limitation, statements regarding the intended design, detection capability and applications of VisionRF, GhostSight, DeepWave RF and the Company’s electronic-warfare and spectrum-monitoring payload concepts; the intended integration of sensing payloads with the VARAN and TALON platforms and with the STRATUM environment; and the Company’s commercialization efforts with SaverOne Ltd.

Forward-looking statements are not guarantees of future performance, are based on management’s current expectations and assumptions as of the date of this press release, and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied, including, but not limited to: the fact that substantially all of the platforms, payloads, sensing technologies and software described in this press release are in development, have not completed testing, qualification or independent third-party validation, are not commercially available, have not generated material revenue, and may never be completed, certified, produced at scale or adopted by any customer; the Company’s need to raise substantial additional capital to fund development and its ability to do so on acceptable terms or at all; the substantial dilution to existing stockholders resulting from sales of common stock under the Company’s at-the-market offering programs, conversions of the Company’s outstanding convertible debentures, exercises of outstanding warrants and shares issuable as consideration in acquisitions and strategic transactions; the Company’s history of operating losses, accumulated deficit and working capital deficiency, and the substantial doubt regarding the Company’s ability to continue as a going concern described in its most recent periodic report; the Company’s ability to satisfy the continued listing standards of The Nasdaq Stock Market, including the minimum bid price requirement, and the anticipated effects of the reverse stock split approved by the Company’s stockholders; the Company’s dependence on government procurement processes, competitive solicitations, budget appropriations and program funding, none of which has resulted in an award, contract or order to the Company; the risks of pursuing sales to foreign governments and foreign defense ministries, including procurement delays, offset requirements, political and geopolitical developments and the absence of any binding commitment; U.S. and non-U.S. export control, licensing, technology transfer, defense trade registration and economic sanctions requirements applicable to the technologies described in this press release, including the International Traffic in Arms Regulations and the Export Administration Regulations, and the risk that required authorizations are delayed, conditioned or denied; the Company’s ability to obtain, protect and enforce intellectual property rights and the risk that pending patent applications do not issue; risks relating to acquisitions, integration and reliance on third parties, partners, suppliers and subcontractors; and the other risks and uncertainties described under “Risk Factors” in the Company’s Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q and its Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission.

All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release and in the Company’s SEC filings. VisionWave undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Investors are cautioned not to place undue reliance on these forward-looking statements.

Contact for Investors: investors@vwav.inc

The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in the YMRS total score (3.1 points; p=0.045) and CGI-BP Severity of Mania score (0.4 points; p=0.024)

RAP-219–treated patients had a 15.4-point mean reduction in YMRS total score from baseline at Week 3

All 11 items measured by the YMRS improved numerically compared to placebo at Week 3, with improvements in irritability, thought content, disruptive-aggressive behavior, and sexual interest reaching nominal significance

RAP-219 was well tolerated; all treatment-emergent adverse events during the treatment period were mild or moderate

Company to host a conference call today at 8:00 a.m. ET

BOSTON and SAN DIEGO, Oct. 20, 2026 (GLOBE NEWSWIRE) — Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced positive topline results from its Phase 2 trial of RAP-219 in adults with acute bipolar mania. The trial met its primary endpoint, with RAP-219 achieving a 3.1-point placebo-adjusted improvement in the Young Mania Rating Scale (YMRS) total score at Week 3 (mean reduction from baseline of 15.4 points with RAP-219 versus 12.3 points with placebo (p=0.045). RAP-219 was well-tolerated, with no severe treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) observed over the treatment period. These results establish clinical proof-of-concept for RAP-219 and its novel TARPγ8-selective mechanism in bipolar mania, supporting progression to Phase 3 trials which are expected to begin in the second half of 2027.

“For people with bipolar disorder, the challenge isn’t just finding a treatment that’s efficacious. It’s finding one they can tolerate and stay on,” said Abraham N. Ceesay, chief executive officer of Rapport. “Side effects drive discontinuation, and discontinuation drives relapse. RAP-219 has the potential to break that cycle with the first new mechanism of action for bipolar mania in decades. Together with our positive Phase 2 focal epilepsy data, these results strengthen RAP-219’s profile across each indication we are pursuing and show it delivering on its potential as a pipeline-in-a-product with two indications that both represent multibillion dollar market opportunities. We look forward to engaging with the FDA on Phase 3 in bipolar mania, alongside our ongoing Phase 3 epilepsy programs.”

This randomized, double-blind, placebo-controlled Phase 2 trial, conducted in the United States, enrolled 253 adults with bipolar I disorder (BD) experiencing an acute manic episode (YMRS≥25 at baseline). During the screening period, all treatments indicated for BD and all anxiolytics and hypnotics were discontinued. Lorazepam was allowed as a rescue medication at protocol-defined doses, and its use required an AE to be recorded, regardless of whether the symptom(s) were judged to be due to a pre-existing condition.

Eligible patients received 0.75 mg of RAP-219 once daily (following a two- or four- day titration) or placebo for three weeks in an inpatient setting. Mean baseline YMRS total score was 36.9 in the RAP-219 arm and 35.8 in the placebo arm. Topline efficacy and safety data reported are from the three-week treatment period. Safety data from the eight-week post-treatment period will be presented at a future medical conference.

RAP-219 Demonstrated Statistically Significant Improvement in Manic Symptoms

• The trial met its primary endpoint, with RAP-219 achieving a statistically significant 3.1-point least squares (LS) mean improvement over placebo in YMRS total score at Week 3 (p=0.045).
• RAP-219–treated patients had an LS mean decrease of 15.4 points in YMRS total score at Week 3 from a baseline of 36.9.
• All 11 YMRS items improved on RAP-219 compared to placebo at Week 3, with improvements in irritability, thought content, disruptive-aggressive behavior, and sexual interest reaching nominal significance (p<0.05).
• RAP-219 showed progressive improvement in the placebo-adjusted YMRS scores over the 3-week treatment period (0.9 at Week 1, 2.2 at Week 2, and 3.1 at Week 3).
• RAP-219 also demonstrated a statistically significant improvement in mania severity score versus placebo at Week 3 as measured by the Clinical Global Impression—Bipolar Version (CGI-BP) mania severity scale, the pre-specified secondary endpoint (0.4; p=0.024).

RAP-219 Was Well-Tolerated

During the three-week treatment period, based on safety and tolerability data^*:

• The incidence of treatment-emergent adverse events (TEAEs) was similar between RAP-219 and placebo (51.6% vs 52.8%), as was the incidence of psychiatric TEAEs (34.9% vs 33.1%).
• All TEAEs were mild or moderate in severity, and there were no serious adverse events (SAEs); 3.2% of patients on RAP-219 discontinued due to a TEAE compared with 0.8% placebo.
• TEAEs occurring in ≥5% of participants in either group (RAP-219 vs placebo) were agitation (16.7% vs 9.4%), insomnia (14.3% vs 15.0%), restlessness (8.7% vs 7.9%), anxiety (7.1% vs 5.5%), headache (5.6% vs 10.2%), and nausea (5.6% vs 1.6%). Those considered treatment related by the investigator were agitation (3.2% vs 1.6%), insomnia (3.2% vs 0.8%), restlessness (1.6% vs 0%), anxiety (0.8% vs 0.8%), headache (0.8% vs 4.7%), and nausea (3.2% vs 0.8%).
  • The most common TEAE on RAP-219 was agitation, generally occurring in the first week and lasting a median duration of two days in both the RAP-219 and placebo groups. In both groups, this was considered unrelated in >80% of patients.
• Adverse effects commonly associated with current bipolar mania medications, including orthostatic hypotension, akathisia, and extrapyramidal symptoms were not reported. Somnolence was reported less often with RAP-219 (0.8%) than placebo (3.1%).

“In this proof-of-concept study, RAP-219 demonstrated statistically significant improvement across measures of mania symptoms as well as a favorable tolerability profile,” said Jeffrey Sevigny, M.D., chief medical officer of Rapport. “This is important because tolerability issues lead many patients to discontinue their therapies. These results continue to build our confidence in the safety profile of RAP-219, and the insights learned from this study will guide us in optimizing the Phase 3 design in bipolar mania. Finally, we are deeply grateful to everyone who made this study possible, including participating patients and their families, the investigators and site staff, and our dedicated employees.”

“There hasn’t been a new mechanism to treat bipolar mania in decades. In this study, RAP-219 achieved statistically significant improvement in manic symptoms with an encouraging tolerability profile, underscoring the promise of this novel mechanism,” said Gary Sachs, M.D., founding director of the Bipolar Clinic and Research Program at Massachusetts General Hospital and associate clinical professor of psychiatry at Harvard Medical School. “Importantly, clinical benefit was seen consistently across all measures, with the greatest improvements in symptoms that tend to drive hospitalization for acute mania patients. What is encouraging about the tolerability profile is what was not seen on RAP-219–the somnolence, akathisia, and extrapyramidal symptoms that often cause patients to discontinue treatment. Based on these results, RAP-219 has the potential to become a mainstay of treatment for acute mania.”

Next Steps and Upcoming Milestones

Rapport plans to meet with the U.S. Food and Drug Administration (FDA) in the first quarter of 2027 to discuss the Phase 2 data and registrational trial design for RAP-219 in bipolar mania. Initiation of two Phase 3 trials of RAP-219 in acute bipolar mania is expected in the second half of 2027. Additional data from the Phase 2 trial will be presented at a future medical meeting.

Upcoming milestones include:

• Focal onset seizures (FOS): FOCUS 1 and FOCUS 2 pivotal Phase 3 trials are enrolling.
• FOS open-label long-term safety trial: Initial data from the long-term open-label extension of the Phase 2a trial are expected in the fourth quarter of 2026.
• Bipolar mania: End-of-Phase 2 meeting with the FDA expected in the first quarter of 2027; initiation of two Phase 3 pivotal trials expected in the second half of 2027.
• Long-acting injectable (LAI): Phase 1 pharmacokinetic (PK) data for an LAI formulation of RAP-219 are expected in the third quarter of 2027.
• Primary generalized tonic-clonic seizures (PGTCS): Phase 3 trial is expected to begin in the first half of 2027.
• RAP-641: Phase 1 preliminary results are expected in the second half of 2027.
• Financial position: As of June 30, 2026, Rapport had $436.1 million in cash, cash equivalents and short-term investments, excluding restricted cash, expected to fund operations into the second half of 2029, beyond expected topline data from the Company’s Phase 3 program in focal onset seizures.

^* Safety and tolerability data as of interim database lock, September 16, 2026.

Conference Call Information
Rapport Therapeutics will host a conference call and live webcast at 8:00 a.m. ET / 5:00 a.m. PT on October 20, 2026, to discuss the data and provide a business update. Individuals interested in listening to the live conference call may do so by dialing (800) 715-9871 for U.S and Canadian callers and (646) 307-1963 for other locations and reference conference ID 3120573, or from the webcast link in the “Investors” section of the Company’s website at www.rapportrx.com. A webcast replay will be available in the “Investors” section of the Company’s website for 90 days following the completion of the call.

About the Young Mania Rating Scale (YMRS)
The Young Mania Rating Scale (YMRS) is a clinician-administered tool used to measure the severity of manic symptoms in people with bipolar disorder. It is the most widely used rating scale in mania research. The YMRS assesses 11 core symptoms of mania: elevated mood, increased activity and energy, sexual interest, sleep, irritability, speech, thought disorder, thought content, disruptive or aggressive behavior, appearance, and insight. Four of these symptoms (irritability, speech, thought content, and disruptive or aggressive behavior) are weighted more heavily to reflect their clinical significance. Clinicians rate each symptom from a clinical interview and the patient’s reported symptoms over the preceding 48 hours. Total scores range from 0 to 60, with higher scores indicating more severe mania.

About the Clinical Global Impression–Bipolar Version (CGI-BP)
The Clinical Global Impression–Bipolar Version (CGI-BP) is a clinician-rated scale adapted from the widely used Clinical Global Impression scale to assess illness severity and change in people with bipolar disorder. Clinicians rate mania, depression, and overall bipolar illness separately. The CGI-BP mania severity score reflects the clinician’s overall judgment of how severe a patient’s manic symptoms are, based on clinical experience with patients with bipolar disorder. Scores range from 1 (normal, not ill) to 7 (among the most extremely ill patients), with higher scores indicating more severe mania. CGI-BP mania severity is commonly used as a complement to symptom-based scales such as the YMRS by capturing the clinician’s overall view of illness severity.

About RAP-219
RAP-219 is an investigational and potential first-in-class, clinical-stage TARPγ8-specific AMPA receptor (AMPAR) negative allosteric modulator (NAM). Whereas AMPARs are distributed widely in the central nervous system, the receptor associated protein (RAP) TARPγ8 is expressed only in discrete brain regions, including the hippocampus and neocortex, where focal seizures often originate. By contrast, TARPγ8 has minimal expression in the hindbrain, where drug effects are often associated with intolerable adverse events. With this precision approach, the Company believes RAP-219 has the potential to provide a differentiated profile as compared to traditional neuroscience medications. Due to the role of AMPA biology in various neurological disorders and the selective targeting of TARPγ8, the Company believes RAP-219 has pipeline-in-a-product potential and is evaluating the compound as a potential treatment for patients with focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. A long-acting injectable formulation of RAP-219 is also in development and could be the first of its kind in epilepsy.

About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological and psychiatric disorders. The Company’s founders made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain, which form the basis of Rapport’s RAP technology platform. The platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, which is designed to achieve neuroanatomical specificity through selective targeting of a RAP expressed only in discrete regions of the brain. The pipeline is anchored by the Company’s epilepsy portfolio, including FOS and primary generalized tonic-clonic seizures, as well as bipolar mania. The Company is also advancing additional discovery and preclinical programs leveraging its platform, including in chronic pain and migraine and in hearing and vestibular disorders.

Availability of Other Information About Rapport Therapeutics
Rapport Therapeutics uses and intends to continue to use its Investor Relations website and LinkedIn (Rapport Therapeutics) as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company’s Investor Relations website and LinkedIn, in addition to following the Company’s press releases, SEC filings, public conference calls, presentations, and webcasts. The contents of the Company’s website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: the clinical development of RAP-219 for the treatment of FOS, PGTCS and bipolar mania, including the initiation, timing, progress, results and future data releases of our ongoing and planned clinical trials, including the long-term open-label extension of the Phase 2a trial in FOS, the FOCUS 1 and FOCUS 2 pivotal Phase 3 trials, the Phase 1 trial for a long-acting injectable formulation of RAP-219, the Phase 1 trial for RAP-641 and the Phase 3 trial of RAP-219 in PGTCS; expectations and timing of upcoming regulatory interactions, including an End-of-Phase 2 Meeting with the FDA for RAP-219 the anticipated planning activities for a potential Phase 3 trial in bipolar mania; expectations for a LAI formulation of RAP-219; the potential of the Company’s RAP technology platform; expectations for the efficacy, tolerability, and commercial potential of RAP-219; and expectations for the Company’s uses of capital, expenses and financial results, including its expectations regarding cash runway into the second half of 2029.

Forward looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect Rapport’s business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the Company’s research and development activities; Rapport’s ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the Company’s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; Rapport’s ability to attract, integrate and retain key personnel; risks related to the Company’s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining Rapport’s intellectual property protections; and risks related to the competitive landscape for Rapport’s product candidates; as well as other risks described in “Risk Factors,” in the Company’s Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Rapport’s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Rapport’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Rapport expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Contact
Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
investors@rapportrx.com

Casino Group becomes PLESIO

The Group is changing its name to PLESIO, adopting a new identity that underscores its positioning in convenience retail. This change applies to the Group. Its seven brands (Monoprix, Casino, Spar, Vival, Cdiscount, Franprix and Naturalia) will retain their names and identities.

Since 2024, the Group has put convenience retail at the heart of its business and strategy. Its new identity reflects its ambition to build a retail business that brings people together and responds to the needs of each local community. This ambition is supported by the Group’s Renouveau 2030 strategic plan, which focuses on three key markets: daily food shopping, quick meal solutions and new everyday services.

Philippe Palazzi, CEO of PLESIO said :

«With our new identity, PLESIO, we are entering the next stage of the Group’s development, driven by a clear belief: the future of retail lies in convenience. PLESIO brings our seven brands together under one name, with a shared ambition: to grow a business that puts people first, meets their everyday needs and strengthens connections within communities. We will roll out our store concepts, expand our quick meal solutions and services, and equip our franchise partners to succeed. Our commitment is the same across all our brands: to serve our customers well ».

A name and an identity that reflect convenience retail

PLESIO, meaning “closeness” in Greek, was chosen to unite the seven brands around the Group’s vision. Short, simple and memorable, the name captures the pleasure of welcoming customers and serving them well.

A Group that supports its brands

PLESIO creates a clear distinction between the Group and the Casino brand, which continues its journey with its stores, its customers and its strong local ties. The new PLESIO identity unites brands that each have their own positioning and their own way of bringing convenience retail to life.

The Group provides its brands with shared resources and expertise to help them roll out their store concepts faster, refurbish their stores and expand their quick meal solutions and new everyday services. It is also strengthening its role as a franchisor, supporting its shopkeepers while respecting their freedom to run their own businesses.

Unveiled today, the new identity will be rolled out gradually across the Group’s internal and external communications materials.
The change to the company’s registered name will be submitted to shareholders for formal approval at the next General Meeting, to be held in 2027.

ABOUT PLESIO

PLESIO is France’s leading convenience retail network, with 25,000 employees, nearly 6,500 stores and €12.5 billion in business volume in 2025. With a history spanning more than 125 years, the Group brings together seven brands: Monoprix, Casino, Spar, Vival, Cdiscount, Franprix and Naturalia. It is growing across three key markets: daily food shopping, quick meal solutions and new everyday services, with one mission: to serve customers well, in store and online, by adapting its offering to people’s lifestyles and the needs of each local community.

Contacts servicedepresse@plesio.fr / + 33 (0)1 78 68 00 38 Stéphanie Abadie sabadie@plesio.fr / +33 (0)6 26 27 37 05 Christophe Piednoël cpiednoel@plesio.fr / +33 (0)6 15 19 17 55

 

Attachment

• PR Casino Group becomes PLESIO_20 october 2026

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Man Group PLC
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Gamma Communications plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	19/10/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	NO

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	0.25p ordinary
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:
(2)   Cash-settled derivatives:	1,260,442	1.41
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	1,260,442	1.41

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
0.25p ordinary	Equity swap	Reducing a long position	24,831	10.9050 GBP
0.25p ordinary	Equity swap	Reducing a long position	6,610	10.9050 GBP
0.25p ordinary	Equity swap	Reducing a long position	4,681	10.9088 GBP

        
(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii)        Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	20/10/2026
Contact name:	Graham Keene
Telephone number:	+44 20 7144 2259

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Disclosure of treasury shares transactions carried out from October 12 to October 16, 2026

Attachment

• BUREAU VERITAS – Reporting agrégé du 12 octobre au 16 octobre 2026 (vENG)

• New Fire TV experience uses the familiar mechanics of streaming discovery to help people find their next night out
• Users can browse participating pubs and bars by “genre”, invite friends and receive a weekly credit for a Heineken or Heineken 0.0
• The launch comes as over half of adults worldwide say they would go out more often if discovering where to go was as easy as discovering something to watch

AMSTERDAM, Oct. 20, 2026 (GLOBE NEWSWIRE) — We’re all familiar with the new era of TV viewing: abundant choice, personalised recommendations and effortless discovery. Streaming has transformed how we discover entertainment, with something to watch just seconds away. Now, that same approach can help people discover where to go out, too.

As much as people love the ease of streaming, they still crave time together IRL. The challenge is that organising a night out can often feel like too much hassle compared to how effortless entertainment discovery has become. In a poll of 15,000 adults worldwide, over half (55%) say they would go out more often if discovering where to go was as easy as discovering something to watch, while almost two-thirds (59%) say they would be more likely to try somewhere new if they had recommendations tailored to their interests and mood.

To make getting together as simple as saying yes to another episode, Heineken^®, the champion of IRL socialising, has collaborated with Amazon to launch ‘Pubscription’, the first streaming service for nights out.

Currently being piloted in the UK, the new Fire TV experience takes inspiration from the simplicity and personalisation of streaming, applying the same approach of deciding what to watch to where to go out. The app helps you find a pub or bar that matches your mood, invite friends and enjoy a free weekly Heineken or Heineken 0.0 together.

Nabil Nasser, Global Head of Heineken, said: “At Heineken, we believe life is better when it’s shared. But as our lives become increasingly digital, creating those moments of real-world connection has never felt more important.

Pubscription uses the simplicity we’ve come to expect from streaming to do something very human: help friends get together, discover a great pub and spend time with each other.

Technology can give us endless ways to be entertained, but nothing replaces the simple pleasure of getting together over a Heineken.”

Developed in collaboration with Brand Innovation Lab, the creative arm of Amazon Ads, Pubscription allows users aged 18+ to browse participating pubs and bars by “genre”, depending on the kind of night they’re after, from lively sports pubs to relaxed local hangouts with friends. Users can subscribe for free via the age-gated Pubscription app on Fire TV and redeem their weekly voucher on their smartphone. They can then invite friends to join them and discover new places together. Each month, Subscribers will receive four vouchers, which can be redeemed for a Heineken or Heineken 0.0 at any participating Star Pub, with a limit of one redemption per week.

Notes to editors
Media contact:
heinekenpubscription@wearetheromans.com

Research Credits:
*Heineken commissioned a survey of 15,000 respondents across the United States, United Kingdom, Spain, Brazil, France, Romania, United Arab Emirates, South Africa, India, South Korea.

The global poll of 15,000 adults found:

• Out of those that stream, over half (55%) do so after 6pm on weekends, rising to almost two thirds (63%) on weekday evenings.
• Almost a third (30%) say they make spontaneous plans to meet friends less often than they did five years ago.
• One in three (31%) say they value memories with friends and family most when going out and socialising.
• Over two in five (41%) say having IRL conversations is one of the main reasons they value going out.

*Separately, Heineken commissioned Statista to supply global data on streaming and socialising between 2022 and 2025, which shows the rise in streaming:

• Globally, people spent more than two and a half hours a day streaming in 2025, compared with just half an hour socialising, showing how central digital entertainment has become to daily life. Pubscription aims to channel that same enthusiasm into discovering great nights out.
• Annual content viewing hours reached 748 billion in 2025, up 33 billion year-on-year.

About Heineken^®
HEINEKEN^® is the world’s most international brewer. It is the leading developer and marketer of premium beer and cider brands. Led by the Heineken^® brand, the Group has a portfolio of more than 300 international, regional, local and specialty beers and ciders. We are committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through “Brewing a Better World”, sustainability is embedded in the business. HEINEKEN^® has a well-balanced geographic footprint with leadership positions in both developed and developing markets. We employ over 85,000 employees and operate breweries, malteries, cider plants and other production facilities in more than 70 countries. Heineken^® N.V. and Heineken^® Holding N.V. shares trade on the Euronext in Amsterdam. Prices for the ordinary shares may be accessed on Bloomberg under the symbols HEIA NA and HEIO NA and on Reuters under HEIN.AS and HEIO.AS. HEINEKEN^® has two sponsored level 1 American Depositary Receipt (ADR) programmes: Heineken^® N.V. (OTCQX: HEINY) and Heineken^® Holding N.V. (OTCQX: HKHHY)

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f5c7c65d-627b-4e4d-b167-465a64edf410

BEIJING, Oct. 20, 2026 (GLOBE NEWSWIRE) — Zhihu Inc. (“Zhihu” or the “Company”) (NYSE: ZH; HKEX: 2390), a leading online content community in China, today announced that the ordinary resolution relating to the Company’s previously announced subscription, through a wholly owned subsidiary, for a limited partnership interest in Tianjin Lisi Xingshen Equity Investment Partnership (Limited Partnership), with a capital commitment of RMB1.5 billion, and the related transactions, as set forth in the notice of extraordinary general meeting dated September 24, 2026, has been duly passed at the extraordinary general meeting held in Beijing, China today.

About Zhihu Inc.

Zhihu Inc. (NYSE: ZH; HKEX: 2390) is a leading online content community where people come to find solutions, make decisions, seek inspiration, and have fun. Since the initial launch in 2010, Zhihu has grown into the largest Q&A-inspired online content community in China. For more information, please visit https://ir.zhihu.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC and the Hong Kong Stock Exchange. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

For investor and media inquiries, please contact:

Zhihu Inc.
Email: ir@zhihu.com

Christensen Advisory
Roger Hu
Tel: +86-10-5900-1548
Email: zhihu@christensencomms.com